Krm Ayurveda Ltd. · NSE:KRMAYURVED
Krm Ayurveda — Investor Presentation (June 2026)
36 slides from Krm Ayurveda's investor presentation, Jun 22, 2026
Slide 1: Investor Presentation filing letter to NSE
KRM AYURVEDA LTD (Formerly Known as KRM Ayurveda Private Limited) 22" June, 20 2026 Scrip Code: KRMAYURVED To The Manager National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra East Mumbai- 400 051 of Sub: Investor Presentation under Regulation 30 read with Para A of Sche
Slide 2: Investor Presentation 2026
& vy) SN NH Kim Say bras ayurveda Investor Presentation 2026 Healing With Nature, Rooted In Science.
Slide 3: Safe Harbor Statement
astate’ Safe Harbor Statement Bgurveda This presentation and the accompanying slides (The Presentation), which have been prepared by KRM Ayurveda Limited (The Company) solely for informational purposes, do not constitute any offer, recommendation, or invitation to purchase or subscribe for any secur
Slide 4: Company Overview
Company Overview
Slide 5: KRM Ayurveda Limited An Ayurvedic Healing Company
a tathtes KRM Ayurveda Limited An Ayurvedic Healing Company KAM 5 * Established in 2019, integrating authentic Ayurveda with modern practices, expanded across Hospitals & Clinics in multiple cities in India. * Originated as a Kidney-specialty hospital; now offering into multi-specialty Ayurvedic hea
Slide 6: Company milestones timeline
First Hospital & ] Revenue Breakthrough 2026 + Established the first hospital in Delhi. Public Market Debut * Generated hospital el & Operational revenue for the first ay Expansion time, marking a new growth phase. 2024 ¢ Listed on the NSE, Fal marking a key milestone 2021 in the Company's growth jo
Slide 7: A Philosophy Built on Timeless Ayurvedic Wisdom
A Philosophy Built on Timeless Ayurvedic Wisdom agurveda At KRM Ayurveda, we believe that true healthcare is not just about curing illness but about restoring balance, harmony, and longevity in life. Guided by the 5,000-year- old wisdom of Ayurveda, our philosophy is built on the principle that prev
Slide 8: Visionaries Behind the Mission
Visionaries Behind the Mission Puneet Dhawan Tanya Dhawan Sanchit Hans Managing Director Non-Executive Director Whole-time director Healthcare entrepreneur and __ industry Possesses expertise in health consultancy, Experienced in business administration and professional with over 12 years of experie
Slide 9: Business Overview
Business Overview
Slide 10: Business Model - An Integrated Healthcare Ecosystem
Business Model - An Integrated Healthcare Ecosystem Physical Hospitals, Clinics Products Manufacturing D2C & Online Telehealth * Digital & Direct Distribution GMP certified production facility at * YouTube for educational content IPD & OPD Care Kundli, Haryana Classical & proprietary Ayurvedic * Soc
Slide 11: Geographical Presence - Hospitals & Clinics (1/4)
Geographical Presence - Hospitals & Clinics(1/4) (fi) Ho spilals (i) Presence in India Delhi (1) 30 beds Ce , Delhi a 23 beds* Gurgaon 95 beds Jaipur (1) 20 beds fs Jaipur (2) 30 beds Udaipur 30 beds C States | ©) Cities ee Lucknow |8 beds () Specially Clinics International Exports Bengaluru, Patna,
Slide 12: Glimpse of the Hospitals
Glimpse of the oR m: Korres Investor Presentation
Slide 13: A High Occupancy Ratio - Hospitals & Clinics (2/4)
SHE BL Poort ceed aoe A High Occupancy Ratio - Hospitals & Clinics(2/4) AM is 69% Bed Occupancy) ~<8,400 Arron ) Tight viability check ahead of establishment opening to tailor services to the local community. Demographics and Clinic Preference Competition & Health Awareness: & Usage Location Age Gro
Slide 14: Ensuring Treatment Quality - Hospitals & Clinics (3/4)
Ensuring Treatment Quality- Hospitals & Clinics(3/4) 40 + Physicians T+ Therapists Qualified Ayurvedic Certified Ayurvedic physicians with Bachelor therapists who have of Ayurvedic Medicine and undergone training and Surgery (BAMS) from certification programs accredited institutions covering traditi
Slide 15: Ayurvedic Services Offered - Hospitals & Clinics (4/4)
Ayurvedic Services Offered- Hospitals & Clinics(4/4) agurveds * Clinical & * Supportive Inlegralive Hospital Care Healthcare Wellness Panchakarma In-Patient & Out-Patient Customized Herbal Chakra Healing & Vamana | Virechana | Basti | Signature Ayurvedic care Medicines Preventive & Energy Balancing
Slide 16: A Diverse Product Range at a GMP Certified Production Unit
Sa f eTe. A Diverse Product Range at a GMP Certified Production Unit KAM os Specialized products address KIDNEY & LIVER HEALTH DIGESTIVE CARE SKIN WELLNESS STRESS & LIFESTYLE MANAGEMENT Backed by research, natural herbs, and traditional formulations TOP SELLING PRODUCTS Karma Karma K~Pure Karma Culi
Slide 17: Revenue Bifurcation - Sale of Products & Services
Revenue Bifurcation - Sale of Products & Services ayurveda 46.23% FY26 FY25 FY24 [J Sale of Products [| Sale of Services Particulars FY26 FY25 FY24 Sale of Products 4,701.02 4,923.30 6,063.62 Sale of Services 5,468.05 2,731.97 651.95 TOTAL 10,169.07 7,655.27 6,715.57 16 Investor Presentation
Slide 18: Content Leadership, Strengthening Brand Equity & Patient Engagement
ohhh geainies See Content Leadership, Strengthening Brand Equity & Patient Engagement SEM nn C 8 Lakh+ Followers on YouTube across 3 channels (— \ Talk TO US If The inbox Tor the Best Ayurvedic treatment immediately! . Dr Puneet Dhawan @drpuneetdhawan - 304K subscribers - 1.4K videos Interested in l
Slide 19: Patient Testimonials
Patient Testimonials Mrs. Anju Kumari Mr. Prince Kumar My mother was struggling with polycystic kidney Mr. Garg disease and had tried everything but no effective | had taken several treatments for my acute kidney results were visible. | started finding alternatives The treatment at Karma Ayurveda is
Slide 20: Brand Leverage, Fueling Direct to Consumer Sales
Brand Leverage, Fueling Direct to Consumer Sales 70 Conference on Speaker al TEDx Ayush Young Entrepreneur “Sustainable Healthcare Panoroad 2024 Award 2024 Solutions” 2025 Dr. Puneet Dhawan was invited as a speaker at the renowned TEDx Attended by delegates including AYUSH Felicitated as Young AYUSH
Slide 21: Recognized for Quality and Excellence
Recognized for Quality and Excellence Ministry of Ayush Government of India * ACCREDITE? Received approval Received NABH Received ECHS Received CGHS from Ayush Ministry Accreditations for Empanelment Empanelment to manufacture Delhi & Gurgaon Ayurvedic Medicines Hospital Investor Presentation
Slide 22: The Future Strategy
The Future Slralesy
Slide 23: Growth Strategy
RRAN ACD Te Sabete, A eveda fo} a| (eS 5. Product Portfolio Expansion Expansion of proprietary Ayurvedic 4. Training Courses for formulations and introduction of Therapists wellness product lines as well as strengthen its market reach through a wider distribution Accredited by Rashtriya Ayurveda net
Slide 24: Industry Overview
Industry Overview
Slide 25: India's Private Healthcare Sector Backed by Powerful Demand and Policy Tailwinds
p ae AD ahesfoahs y Saher. India’s Private Healthcare Sector Backed by Powerful Demand and Policy Tailwinds KAM 5 Projected Hospital Forecasted CAGR Market Size by 2034 (2025 - 2034) USD 192.8 Billion 5.29% Key Growth Drivers als = 403 Strong Demand ise Health-Tech Sector * India has only ~1.3 hospi
Slide 26: From Ancient Wisdom to a US$ 200 Billion Opportunity
a tathtes From Ancient Wisdom to a US$ 200 Billion Opportunity India Is Home To The World's Oldest And Most Trusted Ayush (Ayurveda, Yoga & Naturopathy, Unani, Siddha, And Homeopathy) Traditions AYUSH Market (US$ Billion) 200.00 Government Initiatives or Are Expected To Create Nearly 3 Million Jobs
Slide 27: Financial Highlights
Financial Tlighlights
Slide 28: H2 FY26 & FY26 Result Highlights
OE H2 FY26 & FY26 Result Highlights H2 FY26 Revenue from EBITDA PAT PAT Margin Marej Operations a4 1,787.11 Lakhs a4 1,189.73 Lakhs z 5,333.36 Lakhs oS 33.5] oo dio O4oreray 22.31% YoY 30.59% YoY 102.14% YoY 148.84%YoY FY26 d "EBITDA of ~~ Revenue from es PAT Operations Z 3,112.02 Lakhs 0.0% = 10,16
Slide 29: Management commentary
Management Speaking on the Company’s Financial and Strategic Performance, Dr. Puneet Dhawan, Managing Director & Promoter, said: “Our FY26 performance marks a transformational year for KRM Ayurveda as we crossed the 100 Crore Revenue from operations milestone in FY26, while H2 FY26 EBITDA surged ~10
Slide 30: Financial Highlights
of hihss. wi Poort Financial Highlights KAM 5 Revenue from Operations MEEBITDA -e—EBITDA Margin mm PAT —e—PAT Margin 10,169.07 3,112.02 7,655.27 2,012.00 1,914.02 1,121.41 FY25 FY26 FY25 FY26 FY25 FY26 All Amount In @ Lakhs & Margins In % 29 Investor Presentation
Slide 31: Profit & Loss Statement
a tathtes Profit & Loss Statement In lakhs(#) Particulars FY26 FY25 Revenues from Operations 10,169.07 7,655.27 Other Income 62.33 39.70 Total Income 10,231.40 7,694.97 Cost of Material 1,462.48 950.05 Employee costs 2,107.61 1,908.26 Finance Costs 325.08 289.85 Depreciation 114.37 104.39 Other expe
Slide 32: Balance Sheet
On Balance Sheet In lakhs (Z) Equities & Liabilities Assets FY26 FY25 Equity 2,126.08 15.00 Non Current Assets Reserve & Surplus 2,901.53 2,374.53 Property, Plant & Equipment 2,632.33 2,655.44 Share Premium Account 6,443.12 Long term Loans and Advances 131.52 109.33 Net Worth 11,470.73 2,389.53 Defe
Slide 33: Cash Flow Statement
guanine shhinGas Sabete, Cash Flow Statement KAM 5 In lakhs (#) Particulars FY26 FY25 Cash from Operation N2 349 Cash from Investments (3,050) (786) Cash from Financing 3,681 590 Net Cash Flow 743 154 . 32 Investor Presentation
Slide 34: Key Ratios
sates =ohhh Key Ratios KAM 5 In times Current Ratio Debt to Equity 1.31 13.82 1.65 0.00 FY25 FY26 FY25 FY26 33 Investor Presentation
Slide 35: Investment Rationale
a eldinine shhinGas Sabete, Investment Rationale KAM 5 Benefit from the Rapid Growth of the Industry Backward Integrated Manufacturing Capabilities Favorable consumer trends, expanding wellness adoption, GMP-certified manufacturing facility and proprietary and increasing global recognition of AYUSH
Slide 36: Thank You
THANK YOU AKMIL KRM AYURVEDA LIMITED AKMIL STRATEGIC ADVISORS PRIVATE LIMITED Registered Office: A-16 G T Karnal road Industrial Area, Address: Office No. 1011, 10th Floor, Opal Square, Road No. 16, North West, Delhi, India-110033. Wagle Estate, Thane (w)-400 604, Maharashtra, India Phone: +91 92891